MedTrace Logo

Chemotherapy Plus Bone Marrow Transplantation and Filgrastim in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

NCT00004899 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2012-06-12

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing and die. Bone marrow transplantation may be able to replace cells that were destroyed by chemotherapy. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy.

PURPOSE: Phase II trial to study the effectiveness of chemotherapy plus bone marrow transplantation and filgrastim in treating patients who have acute myelogenous leukemia or myelodysplastic syndrome.

Conditions

Interventions

BIOLOGICAL

filgrastim

DRUG

busulfan

DRUG

etoposide

PROCEDURE

autologous bone marrow transplantation

Sponsors & Collaborators

Principal Investigators

  • Martin S. Tallman, MD · Robert H. Lurie Cancer Center

Study Design

Purpose
TREATMENT

Eligibility

Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-10-31
Primary Completion
2004-08-31
Completion
2004-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004899 on ClinicalTrials.gov